At a glance
ClinicalIndex Comparison RecordN/ACompleted· 39 enrolled
Drug / intervention
Positron emission tomography with the tracer [11C]5-hydroxy-tryptophanradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
[11C]5-Hydroxy-tryptophan Positron Emission Tomography for Assessment of Islet Mass During Progression of Type 2 Diabetes
In Brief
A clinical study evaluating Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan for Type2 Diabetes. Completed, enrolled 39 participants.
Detailed Summary
Cross-sectional study to investigate subjects at different stages of type 2 diabetes development with expected stratification of pancreatic islet mass. Non-diabetic individuals were assigned as control. The primary outcome was the \[11C\]5-hydroxy-tryptophan uptake and retention in the pancreas as a surrogate marker for the endogenous islet mass.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType2 Diabetes
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2013
Primary CompletionOct 2015
First PostedNov 2016
TodayJul 2026
First PostedNov 18, 2016
Enrollment StartJan 1, 2013
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 9.6 years ago
Interventions
Positron emission tomography with the tracer [11C]5-hydroxy-tryptophanradiation
Estimation of islet mass by PET using the tracer \[11C\]5-hydroxy-tryptophan